



---

**REPORT TO: MORAY INTEGRATION JOINT BOARD ON 30 NOVEMBER 2023**

**SUBJECT: GRAMPIAN VACCINATION AND IMMUNISATION ANNUAL REPORT 2023**

**BY: VACCINATION PLANNING MANAGER**

**1. REASON FOR REPORT**

1.1 To inform the Board on the development of the first Grampian Vaccination and Immunisation Annual Report 2023.

**2. RECOMMENDATION**

**2.1 It is recommended that the Moray Integration Joint Board (MIJB) acknowledge the findings of the Vaccination and Immunisation Annual Report 2023.**

**3. BACKGROUND**

3.1 The World Health Organisation (WHO) describes vaccines as one of the two public health interventions that have the greatest impact on the world's health, the other being clean water. Vaccination can prevent or reduce the severity of disease, minimise disability and save lives, often in many of the most disadvantaged people in society. It offers excellent value for money by reducing current and future public expenditure on health and social care provision.

3.2 Effective control of vaccine preventable disease requires action across the whole health and care system, and this aligns with the drive to improve outcomes and reduce inequalities.

3.3 The annual report discusses vaccination in the national and local context including; Vaccination Uptake; Equity in Grampian; Quality Improvement in vaccination and Horizon Scanning.

**4. KEY MATTERS RELEVANT TO RECOMMENDATION**

4.1 There has been declines in childhood vaccination uptakes in both Grampian and Scotland. Moray continue to meet the WHO 95% uptake for all childhood routine schedules at 24 months. At 12 months of age, Moray does not meet the

95% uptake for the Rotavirus (94.4%) and at 5 years of age, Moray does not meet the 95% uptake for the 4 in 1 (91.4%) and Measles, Mumps and Rubella (MMR) dose 2 (90.1%) programme.

**Table 1: Completed primary immunisations by 12 months of age, 2022 – 23 by Moray and NHS Grampian**

	Number in	% completed primary course by 12 months								
		Cohort	6-in-1		PCV		Rotavirus <sup>3</sup>		MenB	
			No.	%	No.	%	No.	%	No.	%
Moray	872	842	96.6	840	96.3	823	94.4	839	96.2	
Grampian	5,494	5,257	95.7	5,240	95.4	5,050	91.9	5,124	93.3	

Source: SIRS 15<sup>th</sup> May 2023

**Table 2: Completed primary immunisations by 24 months of age, 2022-23 by Moray and NHS Grampian**

	Number in	% completed primary and booster course by 24 months										
		Cohort	6-in-1		MMR1		Hib/MenC		PCVB		MenB (Booster)	
			No.	%	No.	%	No.	%	No.	%	No.	%
Moray	820	803	97.9	784	95.6	785	95.7	785	95.7	785	95.7	
Grampian	5,269	5,115	97.1	4,932	93.6	4,898	93.0	4,829	91.6	4,858	92.2	

Source: SIRS 15<sup>th</sup> May 2023

**Table 3: Completed primary immunisations and boosters by 5 years of age, 2022-23 by Moray and NHS Grampian**

	Number in	% completed primary and booster course by 5 years										
		Cohort	6-in-1*		MMR1		Hib/MenC		4-in-1		MMR2	
			No.	%	No.	%	No.	%	No.	%	No.	%
Moray	886	855	96.5	843	95.1	842	95.0	810	91.4	798	90.1	
Grampian	6,223	5,974	96.0	5,848	94.0	5,762	92.6	5,528	88.8	5,469	87.9	

Source: SIRS 15<sup>th</sup> May 2023

4.2 Uptake in the teenage (school based) programme saw disruption during 2020–21 due to the covid-19 pandemic. Teams have been carrying out catch up during 2021–22 with Moray. A vaccines for young people national campaign is planned to commence in November to raise awareness and encourage uptake of the Human Papilloma Virus (HPV), Meningococcal groups A, C, W and Y (MenACWY) and combined Diphtheria, Tetanus and Polio (DTP) vaccines

**Table 4: HPV immunisation coverage rates of dose 1 by the end of the school year 2021/22 at S1 and S2 by Moray and NHS Grampian**

	S1 Coverage Rate (%) Dose 1		S2 Coverage Rate (%) Dose 1	
	Female	Male	Female	Male
Moray	87.1	72.4	87.4	86.8
Grampian	83.7	74	88.4	85.3

Source: CHSP School/SIRS

**Table 5: Vaccination with Td, IPV and Men ACWY by the end of the school year 2021/22 by Moray and NHS Grampian**

	S3 Coverage Rate (%)		S4 Coverage Rate (%)	
	Td/IPV	MenACWY	Td/IPV	MenACWY
Moray	77.6	77.8	82.0	82.2
Grampian	77	77.2	86.7	86.4

Source: CHSP School/SIRS

4.3 The adult routine programmes were paused during the pandemic and were subsequently transferred to health board/Health and Social Care Partnership (HSCP) delivery. Moray has made good progress in ensuring all eligible cohorts are offered the vaccines. The shingles coverage is currently 75% which is above Grampian average. The pneumococcal cohort is currently at 47.3% for 65 years and over and 33.1% for 2 -64 at risk cohort which is below Grampian average.

**Table 6: Shingles Zostavax vaccination coverage amongst eligible routine and catch-up cohorts (70 – 79 years). Moray and NHS Grampian 2021-22 and 2022 – 23**

	70 – 79 years % coverage	
	2021 - 22	2022-23
Moray	69.8	75.0
Grampian	53.9	69.5

Source: National Clinical Data Store/SEER

**Table 7: Pneumococcal vaccination coverage amongst aged 65+ and 2-64 at Risk cohorts 1 April 2022 – 31<sup>st</sup> March 2023 by Moray and NHS Grampian**

	% coverage	
	Aged 65+	2 – 64 at risk
Moray	47.3	33.1
Grampian	55.5	36.9

Source: National Clinical Data Store/SEER

4.4 Uptake of seasonal flu and covid-19 vaccinations in Winter 2022/23 was similar in Grampian to elsewhere in Scotland and highest in the oldest age groups. Uptake shows a socioeconomic gradient with highest uptake amongst those identified as least deprived.

4.5 Within Grampian we continue to improve the delivery of all the vaccination programmes. This includes monitoring the proportion of our eligible population who are vaccinated.

## **5 SUMMARY OF IMPLICATIONS**

### **(a) Corporate Plan and 10 Year Plan (Local Outcomes Improvement Plan (LOIP)) and Moray Integration Joint Board Strategic Plan “Partners in Care 2022 – 2032”**

The policy and approach set out in this report is consistent with the ambitions of the MIJB Strategic Plan.

### **(b) Policy and Legal**

None directly associated with this report.

- (c) Financial implications**  
None directly associated with this report.
- (d) Risk Implications and Mitigation**  
None directly associated with this report.
- (e) Staffing Implications**  
None directly associated with this report.
- (f) Property**  
None directly associated with this report.
- (g) Equalities/Socio Economic Impact**  
An Equality Impact Assessment is not required as there are no changes to policy arising from this report and therefore there will be no differential impact on people with protected characteristics. However, individual strategies will comply with the need for an Equalities Impact Assessment and is considered as part of our service planning process.
- (h) Climate Change and Biodiversity Impacts**  
None directly associated with this report.
- (i) Directions**  
None directly associated with this report.
- (j) Consultations**  
Chief Officer; Heads of Services; Chief Financial Officer and Caroline O'Connor, Committee Services Officer have been consulted in the drafting of this report.

## **6 CONCLUSION**

### **6.1 The Grampian Vaccination and Immunisation annual report (Appendix 1) is an opportunity to reflect on the varied activities and improvements that have been achieved over the year.**

Author of Report: Jo Hall, Vaccination Planning Manager, Public Health, NHS Grampian

Background Papers: Appendix 1 Grampian Vaccination and Immunisation Annual Report 2023

Ref: